QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Plant-afternoon
Last week the team came together to give the office plants some much needed TLC.
Turns out there are a fair few green fingers at Quantify!
Whilst we might not be adding gardening to our service offering any time soon, we hope that visitors to the Stockholm office will enjoy our jungle of plants just as much as we do.
Quantify investigates intensified cytarabine dosing in high-risk AML
Quantify’s Mathias Lilja and Johan Mesterton are co-authors on a new study on cytarabine dosing for treating secondary and high-risk AML using a synthetic control arm study design.
Since 1980’s, the standard treatment of acute myeloid leukemia (AML) is cytarabine infusion with anthracycline (7 + 3 regimen). Our latest research at Quantify aimed to assess if higher cytarabine dosing in induction may provide a benefit in older patients with secondary and high-risk […]
Exciting news for those looking to enhance their Market Access and Real World Evidence (RWE) efforts in Finland!
Our capabilities have significantly expanded, allowing us to offer comprehensive support for your Finnish data and access needs.
As the leading provider of Nordic RWE and market access services, we’ve strengthened our Finnish presence to deliver:
▪ End-to-end RWE including patient-level data access, biobanks, Findata permits, statistical analyses, reporting, manuscripts, and other medical communications
▪ Economic modelling, reimbursement dossiers, and strategic support to ensure your product reaches patients in need, through PPB […]
Nordic data – Why all the hype?
The Nordic region (often called Scandinavia) is home to some of the world’s best real-world data (RWD), driving the development of pharmaceuticals and medical devices. As high-quality RWD becomes increasingly important to regulators and payers, it is critical for real-world evidence (RWE) practitioners across the globe to develop a working knowledge of the region’s data characteristics and ecosystem in order to interpret and deploy Nordic RWD.